Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar 13;5(6):831-838.
doi: 10.1016/j.ekir.2020.03.010. eCollection 2020 Jun.

Hemodialysis Does Not Induce Detectable Activation of the Contact System of Coagulation

Affiliations

Hemodialysis Does Not Induce Detectable Activation of the Contact System of Coagulation

Karlien François et al. Kidney Int Rep. .

Abstract

Introduction: Systemic anticoagulation is administered during hemodialysis to prevent clotting of the extracorporeal circuit. The role of contact system activation in thrombin generation during hemodialysis using current era dialyzer membranes is unknown.

Methods: We performed a single-center randomized crossover study. Ten patients treated with hemodialysis underwent 3 standardized hemodialysis sessions. For every patient, each session was performed with a different type of dialyzer membrane (polyphenylene [PP], polymethylmetacrylate [PMMA], polyethylenimine-coated polyacrylonitrile [AN69ST]). Blood samples were collected before and 5, 15, 30, 90, and 240 minutes after blood pump start to evaluate coagulation activation (thrombin-antithrombin complex [TAT], prothrombin fragment 1+2 [PF1+2], activated factor XII [FXIIa], kallikrein, activated factor XI [FXIa]). Plasma of healthy volunteers (n = 20) was used as a reference.

Results: Baseline TAT and PF1+2 levels were higher in hemodialysis patients compared to healthy controls (median [interquartile range] for TAT: 3.3 [2.9-4.2] vs. 2.4 [2.3-2.5] μg/l [P = 0.0002] and for PF1+2: 647 [478-737] vs. 138 [125-254] pmol/l [P < 0.0002]). Despite the use of systemic anticoagulation, TAT further increased during treatment, with the increase starting after 30 minutes (median TAT at t240: 9.0 μg/l (PP), 5.5 μg/l (PMMA), and 7.2 μg/l (AN69ST), all P < 0.05 vs. baseline). Contact system markers FXIIa and kallikrein did not differ significantly between dialysis patients and healthy controls, whereas baseline FXIa levels were significantly lower in dialysis patients compared to healthy controls (P = 0.001). Levels of all contact system markers remained unchanged during hemodialysis with all types of dialyzer membranes.

Conclusion: Routine hemodialysis using systemic heparin anticoagulation induces coagulation activation without measurable contact system activation.

Keywords: blood coagulation; clotting; factor XIIa; factor Xia; hemodialysis; plasma kallikrein.

PubMed Disclaimer

Figures

None
Graphical abstract
Figure 1
Figure 1
Concise overview of the coagulation cascade, including the tissue factor (TF) pathway and the contact system pathway. Thrombin generation markers prothrombin fragment 1+2 (PF1+2) and thrombin–antithrombin complex (TAT) are denoted in red. PF1+2 is a split product when prothrombin is converted into thrombin. Antithrombin binds thrombin and forms the thrombin–antithrombin complex.
Figure 2
Figure 2
Thrombin generation during hemodialysis using different dialyzers. (a) Thrombin–antithrombin complex (TAT) generation and (b) prothrombin fragment 1+2 (PF1+2) generation during hemodialysis. Three outlier values with absolute values shown in brackets are not to scale. AN69-ST, polyethylenimine-coated polyacrylonitrile dialyzer; PMMA, polymethylmetacrylate dialyzer; PP, polyphenylene dialyzer.

References

    1. Verbeelen D., Jochmans K., Herman A.G. Evaluation of platelets and hemostasis during hemodialysis with six different membranes. Nephron. 1991;59:567–572. - PubMed
    1. Pertosa G., Grandaliano G., Gesualdo L., Schena F.P. Clinical relevance of cytokine production in hemodialysis. Kidney Int Suppl. 2000;76:S104–S111. - PubMed
    1. Sagedal S., Hartmann A., Sundstrom K. Anticoagulation intensity sufficient for haemodialysis does not prevent activation of coagulation and platelets. Nephrol Dial Transplant. 2001;16:987–993. - PubMed
    1. Ishii Y., Yano S., Kanai H. Evaluation of blood coagulation-fibrinolysis system in patients receiving chronic hemodialysis. Nephron. 1996;73:407–412. - PubMed
    1. Ekdahl K.N., Soveri I., Hilborn J. Cardiovascular disease in haemodialysis: role of the intravascular innate immune system. Nat Rev Nephrol. 2017;13:285–296. - PubMed

LinkOut - more resources